R.H. Bluestein & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

R.H. Bluestein & Co’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$413K	Hold	600	–	–	0.03%	171
2022 Q2	$355K	Hold	600	–	–	0.02%	210
2022 Q1	$419K	Hold	600	–	–	0.02%	225
2021 Q4	$379K	Sell	600 -500	-45%	-$307K	0.01%	257
2021 Q3	$666K	Sell	1,100 -500	-31%	-$310K	0.03%	175
2021 Q2	$894K	Buy	1,600 +100	+7%	+$50.7K	0.03%	141
2021 Q1	$710K	Sell	1,500 -39,417	-96%	-$19.2M	0.03%	148
2020 Q4	$19.8M	Buy	40,917 +19,667	+93%	+$10.6M	0.88%	40
2020 Q3	$11.9M	Buy	21,250 +810	+4%	+$491K	0.6%	45
2020 Q2	$12.7M	Buy	+20,440	New	+$11.6M	0.71%	47
2015 Q4	–	Sell	-2,050	Closed	-$954K	–	300
2015 Q3	$954K	Buy	+2,050	New	+$1.1M	0.07%	83
2014 Q2	–	Sell	-1,300	Closed	-$390K	–	378
2014 Q1	$390K	Buy	+1,300	New	+$401K	0.03%	228

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

R.H. Bluestein & Co's REGN Position: Q3 2022 in Review

R.H. Bluestein & Co held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2022 at 600 shares worth $413K. The position accounts for 0.03% of the portfolio, ranked #171.

R.H. Bluestein & Co first reported a position in REGN in Q1 2014 and has held it in 12 quarters since. The position peaked at $19.8M in Q4 2020. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

R.H. Bluestein & Co held 600 shares of Regeneron Pharmaceuticals worth $413K as of Q3 2022.
R.H. Bluestein & Co left its Regeneron Pharmaceuticals share count unchanged in Q3 2022.
Regeneron Pharmaceuticals made up 0.03% of R.H. Bluestein & Co's portfolio in Q3 2022, its #171 holding.
R.H. Bluestein & Co first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 12 quarters since.
R.H. Bluestein & Co's Regeneron Pharmaceuticals position peaked at $19.8M in Q4 2020.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.